Concord Biotech Ltd

{"amount":10.7}

{"actualRevenue":2470575000,"estimateRevenue":2845000000,"revenueSurprise":-374425000,"revenueSurprisePercent":-13.16080843585237,"actualEPS":6.03,"estimateEPS":4.998,"surprise":1.032,"surprisePercent":20.64825930372149}

{"actualRevenue":2777660000,"estimateRevenue":2936000000,"revenueSurprise":-158340000,"revenueSurprisePercent":-5.393051771117166,"actualEPS":6.39,"estimateEPS":7.956,"surprise":-1.566,"surprisePercent":-19.68325791855204}

{"description":"Concord Biotech rose 5% after USFDA approved its ANDA for Tofacitinib Tablets in 5 mg and 10 mg strengths, opening access to a US market estimated at $500 million.","url":"https://www.cnbctv18.com/market/concord-biotech-share-price-usfda-approval-tofacitinib-tablets-500-million-drug-us-market-impact-ws-l-19922836.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Concord Biotech's Q4 net profit fell 36.8% to ₹88.8 crore, revenue dropped 24.1%, EBITDA margin shrank, and the board recommended a ₹7.55/share dividend with July 24, 2026 record date.","url":"https://www.cnbctv18.com/market/concord-biotech-share-price-q4-results-profit-revenue-ebitda-margins-dividend-record-date-ws-l-19915938.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"Concord Biotech's standalone net profit fell 26.91% to Rs 42.57 crore in Q2 June 2025, down from Rs 58.24 crore in the previous quarter.","url":"https://www.business-standard.com/markets/capital-market-news/concord-biotech-standalone-net-profit-declines-26-91-in-the-june-2025-quarter-125080801624_1.html","sentiment":"Negative","domain":"Business Standard"}

{"description":"As of July 7, 2025, Concord Biotech's market capitalization is ₹18,431.80 Cr. The 52-week high is ₹2,658.00, with the low not specified. Live NSE/BSE rates are available.","url":"https://www.livemint.com/market/market-stats/stocks-concord-biotech-share-price-nse-bse-s0005516","sentiment":"Neutral","domain":"Mint"}